AR036700A1 - Forma de dosificacion oral solida de simeticona - Google Patents

Forma de dosificacion oral solida de simeticona

Info

Publication number
AR036700A1
AR036700A1 ARP020103669A ARP020103669A AR036700A1 AR 036700 A1 AR036700 A1 AR 036700A1 AR P020103669 A ARP020103669 A AR P020103669A AR P020103669 A ARP020103669 A AR P020103669A AR 036700 A1 AR036700 A1 AR 036700A1
Authority
AR
Argentina
Prior art keywords
dosage form
simethicone
adsorbent
simeticone
oral dosage
Prior art date
Application number
ARP020103669A
Other languages
English (en)
Spanish (es)
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Publication of AR036700A1 publication Critical patent/AR036700A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP020103669A 2001-09-28 2002-09-27 Forma de dosificacion oral solida de simeticona AR036700A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/966,441 US7101573B2 (en) 2001-09-28 2001-09-28 Simethicone solid oral dosage form

Publications (1)

Publication Number Publication Date
AR036700A1 true AR036700A1 (es) 2004-09-29

Family

ID=25511414

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103669A AR036700A1 (es) 2001-09-28 2002-09-27 Forma de dosificacion oral solida de simeticona

Country Status (18)

Country Link
US (3) US7101573B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1297825B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR036700A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE296619T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2002301259C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR0204001A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2405190C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO5390073A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60204403T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1297825T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2243664T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP0203176A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA02009570A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ521657A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL204141B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1297825E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2362569C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200207755B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US7179488B2 (en) 2001-11-29 2007-02-20 Bob Sherwood Process for co-spray drying liquid herbal extracts with dry silicified MCC
EP1509204A4 (en) * 2001-11-29 2005-07-13 Rettenmaier & Soehne Gmbh & Co AGGLOMERATED PARTICLES WITH AN ACTIVE SUBSTANCE PREPARED WITH MELTED MICROCRYSTALLINE CELLULOSE
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
US7341742B2 (en) * 2002-09-30 2008-03-11 L. Perrigo Company Simethicone containing tablet composition and method
EP1563837A1 (en) * 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
CA2559239C (en) * 2004-04-13 2021-04-06 Boehringer Ingelheim International Gmbh Use of simethicone and sodium picosulphate in constipated patients suffering from bloated feeling and gas discomfort during the night
CA2565941A1 (en) * 2004-05-04 2005-11-10 Equitech Corporation Improved nsaid composition
US20060024384A1 (en) * 2004-07-29 2006-02-02 Giordano John A Compositions and methods for nutrition supplementation
US20060024409A1 (en) * 2004-07-29 2006-02-02 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
EP1862184A4 (en) * 2005-03-24 2012-12-19 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION
BRPI0615607A2 (pt) * 2005-08-30 2011-05-24 Lek Pharmaceuticals composição farmacêutica compreendendo perindopril ou seus sais
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
US20080015260A1 (en) * 2006-07-13 2008-01-17 Kiel Laboratories, Inc. Pharmaceutical compositions having improved stability and methods for preparation and use
US20080038410A1 (en) * 2006-08-18 2008-02-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
WO2008056200A1 (en) * 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of simethicone
KR20090088913A (ko) 2006-11-21 2009-08-20 맥네일-피피씨, 인코포레이티드 개질된 방출형 진통 현탁제
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
US8247440B2 (en) 2008-02-20 2012-08-21 Curators Of The University Of Missouri Composition comprising omeprazole, lansoprazole and at least one buffering agent
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) * 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
EP2318035B1 (en) 2008-07-01 2019-06-12 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
EP2947100B1 (en) 2009-01-06 2019-05-08 Galenagen, LLC Oral compositions for the treatment or the prevention of infections by E. Coli
EP3064217B1 (en) 2009-01-06 2018-04-18 Galenagen, LLC Compositions comprising protease, amylase and lipase for use in the treatment of staphylococcus aureus infections
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
JP5410819B2 (ja) * 2009-04-09 2014-02-05 ライオン株式会社 木クレオソート含有固形製剤
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
ES2726978T3 (es) 2011-04-21 2019-10-11 Curemark Llc Compuestos para el tratamiento de trastornos neuropsiquiátricos
US10463611B2 (en) * 2011-06-08 2019-11-05 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
BR112014004879B1 (pt) * 2011-09-08 2020-01-28 Novartis Ag uso de inibidor de aromatase para tratamento de hipogonadismo e doenças relacionadas, composição farmacêutica oral, e kit
CA2853520C (en) * 2011-10-27 2021-11-16 Thomas Julius Borody Electrolyte purgatives
ITMI20112221A1 (it) * 2011-12-05 2013-06-06 Altergon Sa Formulazioni stabili in capsule di gelatina molle di antiaggreganti piastrinici, acidi grassi omega-3 e amilosio
RU2602745C2 (ru) 2011-12-14 2016-11-20 Дисфар Интернэшнл Б.В. Состав с симетиконом
RU2491941C1 (ru) * 2011-12-27 2013-09-10 Вадим Алексеевич Козловский Композиционный энтеросорбент
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
MA41620A (fr) 2015-05-14 2018-01-09 Abdi Ibrahim Ilac Sanayi Ve Ticaret A S Composition pharmaceutique comprenant de la siméthicone et de l'otilonium
JP6724537B2 (ja) * 2015-05-26 2020-07-15 大正製薬株式会社 固形製剤
US10166185B2 (en) * 2015-06-09 2019-01-01 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
WO2016201119A1 (en) * 2015-06-09 2016-12-15 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
US20180311201A1 (en) 2015-06-12 2018-11-01 Santa Farma ?Laç Sanay? A. ?. Oral pharmaceutical composition comprising otilonium bromide and simethicone with certain bulk density and improved dissolution characteristics
EP3364955B1 (en) 2015-10-09 2022-04-20 RB Health (US) LLC Pharmaceutical formulation
MX385008B (es) * 2016-12-14 2025-03-14 Rhein Siegfried Sa De Cv Composicion mejorada de lansoprazol y simeticona y procesos para prepararla.
AU2018250823A1 (en) 2017-04-10 2019-10-17 Curemark, Llc Compositions for treating addiction
CN111132667A (zh) 2017-09-29 2020-05-08 强生消费者公司 固体西甲硅油颗粒及其剂型
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
FR3117780B1 (fr) * 2020-12-22 2024-04-05 Oreal Composition anhydre sous forme de poudre compacte comprenant un sel de magnesium et de la cellulose microcristalline
CN116159032A (zh) * 2023-03-31 2023-05-26 成都恒瑞制药有限公司 盐酸西替利嗪片及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56169622A (en) * 1980-06-03 1981-12-26 Kissei Pharmaceut Co Ltd Method of making solid preparation from oily substance
US4744987A (en) * 1985-03-08 1988-05-17 Fmc Corporation Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
US4851226A (en) 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US4906478A (en) 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5073384A (en) 1989-10-19 1991-12-17 Valentine Enterprises, Inc. Maltodextrin/defoaming composition combinate
US5275822A (en) 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
NZ235876A (en) 1989-11-01 1992-06-25 Mcneil Ppc Inc Pharmaceutical compositions containing effective amount of antidiarrheal composition and antiflatulent effective amount of simethicone
US5075114A (en) 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
JP3177707B2 (ja) 1991-10-08 2001-06-18 堀井薬品工業株式会社 消化管内ガス除去剤
ES2099438T3 (es) * 1992-04-30 1997-05-16 Schering Corp Polvo seco y estable de cefalosporina hidratada para formulacion de suspension oral.
GR1002332B (el) * 1992-05-21 1996-05-16 Mcneil-Ppc Inc. Νεες φαρμακευτικες συνθεσεις που περιεχουν σιμεθεικονη.
CA2110313C (en) * 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
FR2705966B1 (fr) 1993-06-04 1995-08-25 Dow Corning Sa Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
JPH09504293A (ja) * 1993-10-28 1997-04-28 ザ、プロクター、エンド、ギャンブル、カンパニー マグネシウムアルミニウムシリケート及び複数の活性成分を含有した速溶解性剤形
EP0659403B1 (en) 1993-12-15 2001-03-14 National Starch and Chemical Investment Holding Corporation Use of oil adsorbent natural polymer for cosmetic and pharmaceutical applications
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
WO1999063969A1 (en) * 1998-06-08 1999-12-16 Groenewoud Pieter J Stabilized thyroxine medications
US6126967A (en) 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form

Also Published As

Publication number Publication date
AU2002301259B2 (en) 2009-01-22
RU2002125821A (ru) 2004-03-27
DK1297825T3 (da) 2005-09-26
CO5390073A1 (es) 2004-04-30
RU2362569C2 (ru) 2009-07-27
ZA200207755B (en) 2004-03-26
US20070196468A1 (en) 2007-08-23
US7691409B2 (en) 2010-04-06
HU0203176D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2002-11-28
PL204141B1 (pl) 2009-12-31
US7101573B2 (en) 2006-09-05
AU2002301259C1 (en) 2009-07-23
US20030091624A1 (en) 2003-05-15
PT1297825E (pt) 2005-08-31
DE60204403D1 (de) 2005-07-07
ES2243664T3 (es) 2005-12-01
BR0204001A (pt) 2003-09-16
EP1297825A1 (en) 2003-04-02
CA2405190A1 (en) 2003-03-28
US20100135982A1 (en) 2010-06-03
CA2405190C (en) 2010-11-09
ATE296619T1 (de) 2005-06-15
EP1297825B1 (en) 2005-06-01
NZ521657A (en) 2004-05-28
DE60204403T2 (de) 2006-05-04
HUP0203176A2 (hu) 2004-07-28
PL356358A1 (en) 2003-04-07
MXPA02009570A (es) 2004-07-30

Similar Documents

Publication Publication Date Title
AR036700A1 (es) Forma de dosificacion oral solida de simeticona
AR059324A2 (es) Una forma solida de dosificacion oral
BR0311867A (pt) Forma de ministração adesiva a mucosa em forma de pelìcula e uso de um extrato ou de um óleo de cannabis para a produção de uma forma de ministração adesiva a mucosa em forma de pelìcula
CL2008002407A1 (es) Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04).
UY28509A1 (es) Formas de dosificacion de azitromicina con efectos secundarios reducidos
ATE350072T1 (de) Parfümzusammensetzungen
CL2004002017A1 (es) Forma de dosificacion termoformada a prueba de abuso que contiene (a) uno o mas principios activos susceptibles de abuso, (b) opcionalmente sustancias auxiliares, (c) al menos un polimero sintetico o natural de un grupo definido y (d) opcionalmente a
AR018109A1 (es) FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
BR0215193A (pt) Formulações de azitromicina diretamente compressìveis
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
ECSP066553A (es) Formas de administración masticables, no comprimidas dosificadas individualmente.
BRPI0519212A2 (pt) composiÇÕes farmacÊuticas de desintegraÇço oral contendo agentes de manifestaÇço sensorial
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
FI971188A7 (fi) Terapeuttinen vitamiini-kalsium yhdistelmä yksikköannoksena galeenisen tabletin muodossa, menetelmä sen valmistamiseksi ja sen käyttö
BRPI0407065A (pt) Composição de pasta de dentes
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
BR0214706A (pt) Estrutura absorvente envolta
GT200000141A (es) Material cementoso extruible.
BR0111868A (pt) Composições farmacêuticas
BR0314787A (pt) Forma de dosagem de liberação modificada
RU2002105454A (ru) Косметическая маска для лица
EP1570842A3 (en) Composition containing chondroitin sulphate
DE60101370D1 (de) Pharmazeutische zusammensetzungen, die terbinafin enthalten
CR8973A (es) Composicion farmaceutica en forma de una forma de dosificacion solida soluble en agua

Legal Events

Date Code Title Description
FC Refusal